Welcome to our dedicated page for Biocept news (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on Biocept stock.
Biocept, Inc. (symbol: BIOC) is a leading molecular oncology diagnostics company, specializing in the analysis of circulating tumor-associated DNA. The company focuses on both circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) in plasma. Biocept’s mission is to enhance cancer patient outcomes through the advancement of oncology diagnostics.
Utilizing patented and innovative technologies, Biocept delivers clinically relevant prognostic and predictive assessments to physicians, aiding in the treatment course for cancer patients. Their key offering, the Target Selector™ technology, is renowned for its ability to consistently capture extremely rare cells, which may be found in as few as 1 in 50-100 billion blood cells. This technology allows for precise biomarker analysis, assisting in better disease management and treatment decisions.
Beyond direct patient services, Biocept extends its expertise to other laboratory testing providers, academic institutions, research organizations, and biopharmaceutical companies. They play a vital role in clinical trial support, contributing to the development of new cancer therapies.
Biocept’s recent achievements highlight their commitment to innovation and excellence in oncology diagnostics. The company continually strives to expand its technological capabilities and partnerships, ensuring the delivery of high-quality diagnostics solutions to the oncology community.
Biocept, Inc. (Nasdaq: BIOC) announced a one-for-ten reverse stock split effective September 4, 2020, at 5:00 p.m. Eastern Time. This move aims to increase the stock price to meet Nasdaq's minimum bid requirement of $1.00. As a result, ten pre-split shares will combine to form one share, with no fractional shares issued. Stockholders will receive cash for any fractional shares. The common stock will begin trading on a split-adjusted basis on September 8, 2020. Investors can find further details in the Current Report on Form 8-K filed with the SEC on the same date.
Biocept, Inc. (Nasdaq: BIOC) reports significant progress in COVID-19 testing, having received over 21,000 specimens and processed more than 20,000 using RT-PCR technology. The Company distributed approximately 46,000 specimen collection kits and has 34,000 more ready for distribution. Most test results are delivered within 48 hours, with an average reimbursement of $100 per specimen. Biocept anticipates a significant impact on third-quarter revenue from COVID-19 testing as demand continues to rise, supported by increased staffing and automation.
Biocept (Nasdaq: BIOC) announced that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on September 2 at 10:40 a.m. Eastern time. The live presentation can be accessed here and will also be archived on the Investor Relations section of its website. Biocept specializes in liquid biopsy tests for various cancers, using proprietary technology to aid physicians in treatment and monitoring.
Biocept, Inc. (Nasdaq: BIOC) has appointed Dr. Michael C. Dugan as Chief Medical Officer and Medical Director. With over 25 years in the molecular diagnostics field, Dr. Dugan has held prominent roles at companies like Exact Sciences and Roche. His responsibilities will include overseeing medical policy and operations at Biocept's CLIA-certified laboratory. Dr. Dugan aims to enhance the development of assays for cancer treatment and improve market opportunities. Biocept is known for its liquid biopsy technology providing actionable insights for cancer care.
Biocept, Inc. (NASDAQ: BIOC) has announced that President and CEO Michael Nall will present at the Proactive One2One Virtual Investor Forum on August 25 at 1:00 p.m. Eastern time. The event will feature a company overview followed by a Q&A session. Biocept specializes in liquid biopsy tests that provide clinically actionable information for cancer treatment, utilizing its patented Target Selector™ technology for analyzing tumor markers. The company has also expanded its services to include COVID-19 testing to aid in the pandemic response.
Biocept (Nasdaq: BIOC) expands its agreement with MultiPlan to include COVID-19 testing services at a pre-negotiated price. This collaboration enhances access to Biocept's COVID-19 testing alongside its oncology services for over 60 million health plan members across MultiPlan’s networks, which comprise more than 1 million healthcare providers. Biocept has implemented an efficient online ordering system for COVID-19 tests, ensuring timely results, typically within 48 hours, and an average reimbursement of approximately $100 per test.
Aegea Biotechnologies, located in San Diego, announces the issuance of US Patent 10,745,749 for its Primer-Switch technology, enhancing real-time PCR and next-gen sequencing capabilities. This expands Aegea's intellectual property to 11 US patents and 33 foreign equivalents. The Primer-Switch technology is vital for detecting rare genetic events linked to cancer and drug resistance, as well as for improving molecular diagnostics, including COVID-19 tests. Aegea collaborates with Biocept (BIOC) and Tauriga Sciences to advance innovative diagnostic solutions.
Biocept, Inc. (NASDAQ: BIOC) announced the issuance of US Patent number 10,745,749 for its Primer-Switch technology, enhancing its intellectual property for detecting rare cell mutations via circulating tumor DNA (ctDNA) analysis. This second patent strengthens Biocept's position in offering improved detection methods for oncogene mutations. CEO Michael Nall highlighted its potential in accurate mutation detection, aiding physician decision-making in cancer treatment. The company continues to expand its proprietary liquid biopsy technology, essential for diagnosing and monitoring various cancers.
Biocept (Nasdaq: BIOC) has secured a contract to provide COVID-19 testing for skilled nursing facilities managed by a healthcare group across multiple states, predominantly in California. This agreement follows positive feedback regarding Biocept's prompt testing turnaround and customer service. The deal marks Biocept as one of two labs authorized for testing within this system. Additionally, the company has introduced a new online ordering system, enhancing efficiency and reducing costs for clients. This partnership aims to assist healthcare facilities in adhering to compliance mandates.
Biocept, Inc. (Nasdaq: BIOC) reported Q2 2020 revenues of $917,000, a 23% decline year-over-year, primarily due to COVID-19's impact on patient visits. Despite a 16% drop in oncology commercial volume, this was less than the anticipated 40% decline. Revenues for the first half increased 7% to $2.4 million. The company launched COVID-19 testing, receiving over 11,000 specimens, and signed agreements to enhance its testing capabilities. Additionally, Biocept raised $9.6 million through a direct offering, strengthening its balance sheet for future growth.
FAQ
What is the market cap of Biocept (BIOC)?
What does Biocept, Inc. specialize in?
What is Biocept's mission?
What technology is Biocept known for?
Who can benefit from Biocept's services?
What are circulating tumor cells (CTCs)?
How does Biocept’s technology assist physicians?
Does Biocept support clinical trials?
What recent achievements has Biocept made?
Where is Biocept's technology applied?
How does Biocept’s Target Selector™ technology work?
